Bindarit was chosen because it causes dose dependent selective inhibition of monocyte chemotactic proteins CCL2, CCL7, CCL8 and has anti-inflammatory efficacy in animal disease models in vivo. This evidence concerns the gene CCL2 and glycogen storage disease VI.